Financials Aristo Bio-Tech and Lifescience Limited
Equities
ARISTO
INE082101010
Agricultural Chemicals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
101.1 INR | +4.23% |
|
+11.90% | +55.54% |
Valuation
Fiscal Period: März | 2023 |
---|---|
Capitalization 1 | 381.6 |
Enterprise Value (EV) 1 | 568.4 |
P/E ratio | 8.34 x |
Yield | 0.45% |
Capitalization / Revenue | 0.18 x |
EV / Revenue | 0.26 x |
EV / EBITDA | 6.46 x |
EV / FCF | -7,007,713 x |
FCF Yield | -0% |
Price to Book | 1.27 x |
Nbr of stocks (in thousands) | 6,808 |
Reference price 2 | 56.05 |
Announcement Date | 9/4/23 |
Income Statement Evolution (Annual data)
Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net sales 1 | 2,017 | 2,012 | 1,672 | 1,660 | 2,179 |
EBITDA 1 | 68.19 | 45.08 | 43.44 | 54.59 | 87.94 |
EBIT 1 | 63.12 | 39.88 | 35.95 | 43.61 | 72.58 |
Operating Margin | 3.13% | 1.98% | 2.15% | 2.63% | 3.33% |
Earnings before Tax (EBT) 1 | 41.02 | 13.96 | 14.98 | 20.4 | 47.39 |
Net income 1 | 28.28 | 10.07 | 10.76 | 14.5 | 35.62 |
Net margin | 1.4% | 0.5% | 0.64% | 0.87% | 1.64% |
EPS 2 | 5.662 | 2.017 | 2.154 | 2.902 | 6.720 |
Free Cash Flow | - | -55 | -32.38 | -29.42 | -81.12 |
FCF margin | - | -2.73% | -1.94% | -1.77% | -3.72% |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | 0.2500 |
Announcement Date | 6/16/22 | 6/16/22 | 6/16/22 | 1/25/23 | 9/4/23 |
Balance Sheet Analysis
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net Debt 1 | 140 | 192 | 221 | 251 | 187 |
Net Cash position 1 | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.054 x | 4.256 x | 5.096 x | 4.592 x | 2.125 x |
Free Cash Flow | - | -55 | -32.4 | -29.4 | -81.1 |
ROE (net income / shareholders' equity) | - | 8.54% | 8.38% | 10.3% | 15.8% |
ROA (Net income/ Total Assets) | - | 2.79% | 2.65% | 3.44% | 5.13% |
Assets 1 | - | 360.6 | 405.2 | 421.3 | 694.3 |
Book Value Per Share 2 | 22.60 | 24.60 | 26.80 | 29.70 | 44.30 |
Cash Flow per Share 2 | 0.8800 | 1.050 | 0.2200 | 0.8300 | 5.590 |
Capex 1 | 20.8 | 22 | 19.9 | 32.5 | 40.6 |
Capex / Sales | 1.03% | 1.09% | 1.19% | 1.96% | 1.86% |
Announcement Date | 6/16/22 | 6/16/22 | 6/16/22 | 1/25/23 | 9/4/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+55.54% | 8.24M | |
-12.66% | 3.08B | |
-41.63% | 1.57B | |
-16.48% | 1.52B | |
-15.68% | 1.43B | |
-34.44% | 1.4B | |
-12.45% | 1.18B | |
-10.77% | 1.01B | |
+70.09% | 978M | |
-34.84% | 859M |
- Stock Market
- Equities
- ARISTO Stock
- Financials Aristo Bio-Tech and Lifescience Limited